• Explore /
  • Poster
  • / Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

Abstract Poster

Authors

null

Jianliang Yang

Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China

Jianliang Yang , Yongping Song , Zhiming Li , Mingzhi Zhang , Zhen Wang , Hongmei Jing , Li Yu , Huizi Ma , Xiwen Zhao , Wei Li , Wei Meng , Wenzhi Tian , Yuankai Shi , Keshu Zhou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

CTR20192612

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7527)

DOI

10.1200/JCO.2023.41.16_suppl.7527

Abstract #

7527

Poster Bd #

78

Abstract Disclosures

Similar Posters

First Author: Adrienne Sallets

First Author: Lorenzo Falchi

First Author: Mingyuan Sun

First Author: Adolfo Enrique Diaz Duque